NKGen Biotech announces administration of first dose of troculeucel

NKGen Biotech (NKGN) announced the administration of troculeucel, an expanded autologous NK cell therapy, in a stroke patient under a single compassionate use, Investigational New Drug cleared by the U.S. Food and Drug Administration. In collaboration with Dimitri Sigounas, M.D., Associate Professor of Neurological Surgery and Amarendra Neppalli, M.D., Director of Transplant and Cellular Therapy at George Washington University Medical Center, Washington, D.C., NKGen has begun to explore the potential therapeutic role of troculeucel in the post-stroke setting. This FDA-cleared single compassionate use IND will be the initial step towards a possible full IND application. Dosing the first stroke patient is part of NKGen’s continued efforts to explore the potential of its NK cell therapy for individuals suffering post-stroke and traumatic brain injury, especially as a means to reduce or prevent